|
|
OJHAS: Vol. 3, Issue
3: (2004 Jul-Sep) |
|
|
Risk Factors for Invasive Epithelial Ovarian
Cancer by Histologic Subtype |
|
|
Jeffrey T. Quirk, Ph.D., Department
of Biology and Health Services, 150 Cooper Science Hall, Edinboro University of
Pennsylvania, Edinboro, PA, USA 16444, Nachimuthu Natarajan, M.S. Division
of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY,
USA 14263 Curtis J. Mettlin, Ph.D. Division
of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY,
USA 14263 Kirsten B. Moysich, Ph.D. Division
of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY,
USA 14263 Helen Swede, Ph.D. Connecticut
Tumor Registry, Connecticut Department of Public Health, Hartford, CT, USA 06134
|
|
|
|
|
|
Address For Correspondence |
|
Jeffrey T. Quirk, Ph.D.,
Department of Biology, State University of New York
Jamestown Community College, 525 Falconer Street
Jamestown, NY, USA 14702
E-mail: jtq@velocity.net
|
|
|
Quirk JT, Natarajan N,
Mettlin CJ, Moysich KB, Swede H. Risk Factors for Invasive Epithelial Ovarian Cancer by Histologic Subtype.
Online J Health Allied Scs.2004;3:2 |
|
Submitted: Jul 27,
2004; Accepted: Oct 8, 2004; Published:
Oct 18,
2004 |
|
|
|
|
|
|
|
|
Abstract: |
It is unclear whether the different
histologic subtypes of epithelial ovarian carcinoma have different risk factors. We
investigated the relationships between selected epidemiologic variables (i.e., parity,
family history of ovarian cancer, oral contraceptive use, a history of tubal ligation and
noncontraceptive estrogen use) and the major histologic subtypes of epithelial ovarian
cancer in a hospital-based case-control study of adult women at Roswell Park Cancer
Institute in Buffalo, NY, USA. Multivariate unconditional logistic regression models were
used for statistical analysis. We observed a pattern of increased risk associated with
family history and a pattern of risk reduction associated with parity, noncontraceptive
estrogen use and tubal ligation across all histologic subtype groups. However, we did not
observe a consistent pattern of risk associated with oral contraceptive use. These results
provide some additional support for the hypothesis that the effects of various ovarian
cancer risk factors may differ according to the histologic subtype.
Key Words:
Epithelial ovarian cancer, Histology, Epidemiology, Case-control study
|
|
Ovarian cancer is a devastating gynecological malignancy, with an estimated 100,000
deaths and 165,000 new cases occurring every year worldwide.(1) The ovarian surface is
covered by a single layer of epithelial cells commonly referred to as the surface
epithelium, and approximately 80% of all malignant ovarian tumors are thought to derive
from the surface epithelium and its inclusion glands and cysts.(2,3) Epithelial ovarian
carcinomas are histologically classified into several subtypes according to their
predominant pattern of differentiation, and the most frequently observed subtypes include
serous, endometrioid, mucinous, and clear cell carcinomas. It is uncertain whether the
different epithelial histologic subtypes are epidemiologically heterogeneous.(4,5) Some
recent epidemiologic case-control investigations have reported various differences among
histologic subtypes (6-11), while other studies have not.(12,13) In an effort to provide
more data on this important issue, we conducted a hospital-based case-control study that
assessed whether selected ovarian cancer risk factors differed according to histologic
subtype.
This study was approved by the Institutional Review Board of Roswell Park Cancer
Institute (RPCI) in Buffalo, New York, U.S.A., and informed consent was properly obtained
from all participants. Study subjects included adult women patients admitted to RPCI
between 1982 and 1998 who volunteered to complete a self-administered epidemiologic
questionnaire. The details of this hospital-based data collection system have been
previously described.(14,15) Cases (n = 418) included patients diagnosed with primary
invasive epithelial ovarian cancer of the following major histologic subtypes: serous
carcinomas (n = 284; ICD-O (16) codes 8441, 8460, and 8461), endometrioid carcinomas (n =
65; ICD-O code 8380), mucinous carcinomas (n = 34; ICD-O codes 8470, 8471, and 8480), and
clear cell carcinomas (n = 35; ICD-O code 8310). Cases were predominately Caucasian
(99.3%) and ranged in age from 19 to 86 years (mean age 55.9 ± 13.1 years). Nearly
seventy percent (290/418) of cases were 50 years of age and older. Controls (n = 836)
included patients seen at RPCI who were discharged without a diagnosis of malignancy.
Among a pool of 5,695 eligible patients, controls were randomly selected and
frequency-matched to cases by five-year age intervals for a final case to control ratio of
1:2. Similar to cases, controls were predominately Caucasian (91.9%) and ranged in age
from 18 to 89 years (mean age 55.9 ± 13.2 years).
Epidemiologic information for study subjects was extracted from a database compiled
from the self-administered questionnaires. For the entire epithelial ovarian cancer case
group and for each separate histologic subtype group, multivariate unconditional logistic
regression models (17,18) were used to calculate odds ratio (OR) and 95% confidence
interval (CI) estimates associated with the following risk factors: parity (live births),
a family history of ovarian cancer in a first-, second-, or third-degree relative, oral
contraceptive use, a history of tubal ligation, and noncontraceptive estrogen use. Models
were adjusted for age (continuous), parity (0,=1), family history of ovarian cancer (no, yes),
oral contraceptive use (never, ever), history of tubal ligation (never, ever), and
noncontraceptive estrogen use (never, ever). Further adjustment for potential confounders
such as education, income, cigarette smoking, and geographic area of residence failed to
notably alter point estimates. All data analyses were performed using SPSS for Windows
version 10.0 (SPSS Inc., Chicago, IL).
The results from the logistic regression analyses are presented in Table 1.
Table 1: Logistic regression results for selected ovarian cancer risk factors
according to histologic subtype, Roswell Park Cancer Institute, 1982-1998a
|
Controls (n=836) |
All Cases (n=418) |
Serous Cases (n=284) |
Endometrioid Cases (n=65 |
Mucinous Cases (n=34) |
Clear Cell Cases (n=35) |
|
n |
n |
OR (95% CI)b |
n |
OR (95% CI) |
n |
OR (95% CI) |
n |
OR (95% CI) |
n |
OR (95% CI) |
Parous |
Never |
139 |
100 |
1.0 (referent) |
59 |
1.0 (referent) |
19 |
1.0 (referent) |
10 |
1.0 (referent) |
12 |
1.0 (referent) |
Ever |
688 |
311 |
0.61 (0.53-0.96) |
222 |
0.71 (0.49-1.02) |
43 |
0.53 (0.28-0.99) |
23 |
0.36 (0.15-0.86) |
23 |
0.41 (0.19-0.90) |
1-2 children |
296 |
140 |
0.63 (0.45-0.90) |
96 |
0.63 (0.45-0.90) |
20 |
0.58 (0.29-1.18) |
12 |
0.39 (0.15-1.01) |
12 |
0.47 (0.20-1.15) |
3-4 children |
279 |
145 |
0.69 (0.48-0.98) |
107 |
0.83 (0.56-1.25) |
20 |
0.58 (0.28-1.20) |
8 |
0.34 (0.12-0.97) |
10 |
0.47 (0.19-1.16) |
=5 children |
113 |
26 |
0.31 (0.19-0.53) |
19 |
0.37 (0.20-0.67) |
3 |
0.24 (0.07-0.85) |
3 |
0.31 (0.08-1.27) |
1 |
0.12 (0.01-0.92) |
(Missing) |
9 |
7 |
|
3 |
|
3 |
|
1 |
|
0 |
|
Family History of Ovarian Cancer |
No |
804 |
386 |
1.0 (referent) |
264 |
1.0 (referent) |
61 |
1.0 (referent) |
29 |
1.0 (referent) |
32 |
1.0 (referent) |
Yes |
32 |
32 |
2.08 (1.24-3.48) |
20 |
2.00 (1.11-3.58) |
4 |
1.83 (0.61-5.47) |
5 |
3.41 (1.06-10.96) |
3 |
2.95 (0.83-10.51) |
Oral Contraceptive Use |
Never |
575 |
281 |
1.0 (referent) |
193 |
1.0 (referent) |
48 |
1.0 (referent) |
13 |
1.0 (referent) |
27 |
1.0 (referent) |
Ever |
243 |
128 |
1.22 (0.88-1.68) |
85 |
1.20 (0.84-1.74) |
16 |
0.79 (0.38-1.65) |
20 |
4.58 (1.75-12.00) |
7 |
0.78 (0.27-2.20) |
< years |
135 |
75 |
1.22 (0.84-1.79) |
47 |
1.18 (0.76-1.82) |
9 |
0.71 (0.28-1.75) |
15 |
6.12 (2.20-17.02) |
4 |
0.70 (0.19-2.61) |
>5 years |
108 |
53 |
1.18 (0.78-1.79) |
38 |
1.20 (0.75-1.91) |
7 |
0.91 (0.36-2.28) |
5 |
2.78 (0.81-9.55) |
3 |
0.88 (0.23-3.35) |
(Missing) |
18 |
9 |
|
6 |
|
1 |
|
1 |
|
1 |
|
Noncontraceptive Estrogen Use |
Never |
597 |
322 |
1.0 (referent) |
212 |
1.0 (referent) |
54 |
1.0 (referent) |
29 |
1.0 (referent) |
27 |
1.0 (referent) |
Ever |
217 |
86 |
0.72 (0.53-0.96) |
66 |
0.84 (0.60-1.17) |
9 |
0.40 (0.18-0.90) |
4 |
0.30 (0.09-1.03) |
7 |
0.70 (0.29-1.68) |
(Missing) |
22 |
10 |
|
6 |
|
2 |
|
1 |
|
1 |
|
Tubal Ligation |
Never |
696 |
357 |
1.0 (referent) |
240 |
1.0 (referent) |
57 |
1.0 (referent) |
28 |
1.0 (referent) |
32 |
1.0 (referent) |
Ever |
118 |
47 |
0.84 (0.57-1.24) |
34 |
0.89 (0.57-1.37) |
6 |
0.75 (0.30-1.91) |
5 |
0.68 (0.24-1.96) |
2 |
0.53 (0.12-2.39) |
(Missing) |
22 |
14 |
|
10 |
|
2 |
|
1 |
|
1 |
|
aOdds ratios adjusted for age
(continuous), parity (0, =1), family history (no, yes), oral contraceptive use (never, ever), tubal
ligation (never, ever), and noncontraceptive estrogen use (never, ever)
bOR = odds ratio, CI = confidence interval
Compared to nulliparous women, women who had one or more children had a statistically
significant reduced risk of ovarian cancer in the total case group and in the
endometrioid, mucinous, and clear cell histologic subtype groups. Parous women in the
serous histologic group also experienced a reduced risk, but this finding was not
statistically significant (OR = 0.71; 95% CI = 0.49 - 1.02). Compared to women who did not
have a reported family history of ovarian cancer, women with such a history had an
apparent increased risk for ovarian cancer in all the case groups. The observed risk was
not statistically significant, however, in either the endometrioid (OR = 1.83; 95% CI =
0.61 - 5.47) or clear cell (OR = 2.95; 95% CI = 0.83 - 10.51) histologic groups. Women who
had reported ever using oral contraceptives had a nonsignificant reduced risk for ovarian
cancer in the endometrioid (OR = 0.79; 95% CI = 0.38 - 1.65) and clear cell (OR = 0.78;
95% CI = 0.27 - 2.27) groups, and a nonsignificant increased risk in the total case (OR =
1.22; 95% CI = 0.88 - 1.68) and serous (OR = 1.20; 95% CI = 0.84 - 1.74) groups. Oral
contraceptive users in the mucinous histologic group experienced a statistically
significant increased risk for ovarian cancer in both the ever (OR = 4.58; 95% CI = 1.75 -
12.00) and >5 years of use (OR = 6.12; 95% CI = 2.20 - 17.02) categorizations. This
risk was nonsignificantly elevated (OR = 2.78; 95% CI = 0.81 - 10.51) in the small number
of mucinous cases who had used oral contraceptives for greater than 5 years. We observed
nonsignificant risk reductions for ovarian cancer across all case groups for those women
who had undergone tubal ligation operations, and found that noncontraceptive estrogen
users also had a reduced risk in all case groups, although this observed risk was
statistically significant in only the total case and endometrioid groups.
Most prior epidemiologic studies of epithelial ovarian cancer have combined the
various histologic subtypes in their analyses and have not assessed whether ovarian cancer
risk factors differed according to histologic subtype.(6) Stratifying analyses by
histologic subtype might enable researchers to identify clinically important
subtype-specific risk factors, which ultimately could translate into improved prevention,
detection, and treatment strategies for ovarian cancer. Although not all studies are in
agreement (12,13), the results from recent case-control studies that have explored
histologic subtype-specific associations suggest that the different subtypes are
epidemiologically heterogeneous.(6-11) In particular, some data has been presented that
supports the notion that ovarian cancer risk factors might differ for mucinous and
nonmucinous tumors.(10)
In this hospital-based case-control study, we investigated the relationships between
selected risk factors and the major histologic subtypes of invasive epithelial ovarian
cancer. After statistically controlling for the effects of several potential confounders
in the logistic regression analyses, we observed a pattern of risk reduction across all
histologic groups associated with parity, noncontraceptive estrogen use, and a history of
tubal ligation. A pattern of increased risk across all groups was observed for those women
who had reported a family history of ovarian cancer. Interestingly, no consistent pattern
of risk was associated with the use of oral contraceptives. Women who had reported ever
using oral contraceptives had a nonsignificant reduced risk for ovarian cancer in the
endometrioid and clear cell groups, but a nonsignificant increased risk in the total case
and serous groups. These nonsignificant risk associations were maintained in both the >5 years of use and
>5 years of use categorizations. In contrast to these observed associations, oral
contraceptive users in the mucinous group experienced a statistically significant increase
in risk in both the ever and >5 years of use categorizations. Although we observed only slight
differences in subtype-specific associations related to parity, family history,
noncontraceptive estrogen use, and tubal ligation history, the epithelial histologic
subtypes appear to be epidemiologically more heterogeneous in relation to oral
contraceptive use.
Our findings with respect to the entire epithelial ovarian cancer case group are
consistent with the results of previous epidemiologic studies that have reported reduced
risk associations related to parity and a history of tubal ligation, and an increased risk
association related to a family history of ovarian cancer. We observed a statistically
significant reduced risk for ovarian cancer in those women who had reported using
noncontraceptive estrogens, but most studies that have examined this risk factor have not
provided clear evidence that any real association exists.(4,5,19,20) In contrast to the
large majority of epidemiologic studies, we did not observe a statistically significant
reduced risk for ovarian cancer in those women who had ever used oral contraceptives.
Similar findings have been reported in the literature. For example, in a large prospective
cohort study of U.S. registered nurses, Hankinson and colleagues (21) reported that the
multivariate relative risk of ovarian cancer for ever users of oral contraceptives was
1.08 (95% CI = 0.83 - 1.43).
Two important limitations should be considered in the interpretation of the results
from the present investigation. Since the histologic classification of epithelial ovarian
carcinoma is beset by a number of complexities and difficulties for pathologists (2,22),
we cannot exclude the possibility that potential errors in subtype classification may have
occurred. On the other hand, all of the classification was performed in a specialized
cancer hospital by highly qualified pathologists. Secondly, the small number of cases in
the histologic subtype groups may account for the absence of statistical significance
observed for some of the factors where risk was expected. We would like to emphasize,
however, that our analyses are based on nearly twenty years of data collection at a
regional cancer institution.
In conclusion, the results of this case-control investigation offer some
additional support for the notion that the impact of different ovarian cancer risk
factors, most notably oral contraceptive use, varies across the major epithelial
histologic subtypes. Additional epidemiologic studies with large numbers of ovarian cancer
cases are needed to further explore and resolve the important issue of whether a variety
of risk factors (e.g., reproductive, dietary, behavioral, genetic) differ according to
histologic subtype.
This work was supported by grant CA 09051 from the United States Public Health
Service, and by grant CA 16056 from the National Cancer Institute (USA).
Financial Conflicts of Interest: None
- Parkin DM, Pisani P. Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;
49:33-64.
- Scully RE, Young RH, Clement PB. Atlas of Tumor Pathology, Third Series, Fascicle 23:
Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Washington,
DC: Armed Forces Institute of Pathology, 1998.
- Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology,
endocrinology, and pathology. Endocr Rev 2001;22: 255-88.
- Weiss NS, Cook LS, Farrow DC, et al. Ovarian cancer. In: Schottenfeld D, Fraumeni JF Jr,
editors. Cancer Epidemiology and Prevention, 2nd ed. New York: Oxford; 1996. p. 1040-57.
- Troisi R, Hartge P. Ovarian cancer. In: Goldman MB, Hatch MC, editors. Women and Health.
San Diego: Academic Press; 2000. p. 907-15.
- Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian
cancer by histologic type. Results of a case-control study. Am J Epidemiol
1996;144:363-72.
- Marchbanks PA, Wilson H, Bastos E, et al. Cigarette smoking and epithelial ovarian
cancer by histologic type. Obstet Gynecol 2000; 95: 255-60.
- Whiteman DC, Murphy MF, Cook LS et al. Multiple births and risk of epithelial ovarian
cancer. J Natl Cancer Inst 2000; 92: 1172-7.
- Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and reproductive factors in
relation to ovarian cancer risk. Br J Cancer 2001; 84: 714-21.
- Purdie DM, Webb PM, Siskind V, et al. The different etiologies of mucinous and
nonmucinous epithelial ovarian cancers. Gynecol Oncol 2003;88:S145-8.
- Parazzini F, Chiaffarino F, Negri E, et al. Risk factors for different histological
types of ovarian cancer. Int J Gynecol Cancer 2004;14:431-6.
- Wittenberg J, Cook LS, Rossing MA, et al. Reproductive risk factors for mucinous and
non-mucinous epithelial ovarian cancer. Epidemiology 1999;10:761-3.
- Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer
according to histologic type and invasiveness. Ann Epidemiol 2001;11:568-74.
- Mettlin C. Milk drinking, other beverage habits, and lung cancer risk. Int J Cancer
1989; 43: 608-12.
- Moysich KB, Mettlin C, Piver MS, et al. Regular use of analgesic drugs and ovarian
cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:903-6.
- Percy C, van Holten V, Muir C, editors. International Classification of Diseases for
Oncology, 2nd ed. Geneva: World Health Organization, 1990.
- Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. 1: The Analysis of
Case-Control Studies. Lyon: International Agency for Research on Cancer, 1980.
- Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd ed. New York: Wiley, 2000.
- Harlap S. The epidemiology of ovarian cancer. In: Markman M, Hoskins WJ, editors. Cancer
of the Ovary. New York: Raven Press; 1993: p. 79-93.
- Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer.
Semin Oncol
1998; 25: 255-64.
- Hankinson SE, Colditz GA, Hunter DJ et al. A prospective study of reproductive factors
and risk of epithelial ovarian cancer. Cancer 1995;76:284-90.
- Wheeler JE. Pathology of malignant ovarian epithelial tumors and miscellaneous and rare
ovarian and paraovarian neoplasms. In: Rubin SC, Sutton GP, editors. Ovarian Cancer, 2nd
ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 99-134.
|